The goal of this clinical trial is to learn if individualized accelerated repetitive transcranial magnetic stimulation (rTMS) targeting the inferior frontal cortex combined with symptom provocation works to treat obsessive-compulsive disorders (OCD) in adults. It will also learn about the safety of rTMS over right IFC. The main questions it aims to answer are:
* Does rTMS using a new individualized IFC target relieve participants' OCD symptoms? * What medical problems do participants have when taking rTMS?
Participants will:
* Take rTMS six times per day for 5 consecutive days * Visit the clinic once at baseline, the day and four weeks after treatment for checkups and tests
Volunteer subjects with Obsessive Compulsive Disorders (OCD) according to the Diagnostic and Statistical Manual of Mental Disorders (DSM V) criteria
without associated tics ("Gilles de la Tourette" Syndrome)
Age 18-60 years, right-handed
Disease severity: Yale-Brown Obsessive Compulsive Scale score ≥16 for OCD patients
Abnormal cognitive status (assessed using MoCA with score <24);
Other primary diagnosis than OCD (comorbid mild depression is tolerated)
Comorbid diagnosis of schizophrenia/ psychotic disorder, bipolar disorder, substance abuse or dependance3)
Significant self-harm intent or severe suicidal tendencies within the past year;
Single group
rTMS
Other interventionindividualized rTMS target the IFC with symptom provocation
OCD Symptom Severity Assessed by Y-BOCS
Change from Baseline to 4 weeks after treatment in OCD Symptom Severity
Safety for rTMS targeting IFC
Number of Participants with Treatment-Related Adverse Events
Depression Severity Assessed by HAMD
Anxitey Severity Assessed by HAMA
Clinical Efficacy Assessed by CGI
Click on the lead sponsor to view all of their trials.
